Theravance Biopharma (TBPH) Reports Q4 Loss Per Share of $1.23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2015 Financial Results
March 9, 2016 4:15 PM ESTDUBLIN, IRELAND -- (Marketwired) -- 03/09/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2015. Revenue for the fourth quarter and full year of 2015 was $3.9 million and $42.1 million, respectively. In line with the Company's expectation, the full year 2015 operating loss excluding share-based compensation was $127.8 million, or $181.9 million including share-based compensation of $54.1 million. Cash, cash equivalents, and marketable securities totaled $215.3 million as of December 31, 2015. The year-end cash balance excludes $35.2 million in receivables from collaborative arrangements and a $15.0 million milestone payment from Mylan... More
